Member Info for itsallamess

That's right lewis... long please answer the question!

Long Good job you dont own any shares here, but for us holders it looks great.

But if you are thinking of investing then have a read of the RNS over the past 3 months and you will see how strong we are.

Unless you are just a deramper and are getting a kick out of being negitive and if this is the case hop along

"As CEO, I talk to investors so I don’t promise too much. There must be a time buffer in everything to maintain trust"

That explains why faron deosnt hype things that are not happening like many other AIM companies

Also that's why we constantly get good RNSs out of the blue

So when he says significant "shareholder value" you can believe him

Well done everyone invested here!

After reading the article on marku, my confidence in Traumakine and clevegen is at a all time high...

Not many AIM CEO has a back story like Marku

Fabulous.. and very happy to be apart of the journey

Towards new riddles
40 years ago, Jalkanen thought that the great mysteries of life were being solved in the laboratories of biochemists. It is now necessary to acknowledge that the work is just beginning.
“Exploring the human headgear is just gaining momentum. For example, what is behind Alzheimer's and Parkinson's? They are neural states that combine biological entities. When you learn to control them, you can also make medicines. ”
Their development is left to someone else.
“I’m running out of time. Will be against biology. And do not now type in that it is in poor condition, because I'm pretty good condition. But it is not a secret that I kuusvitonen. "
Jalkanen's goal is now in 2022 and 2023. In that time window, the intention is to get the drugs under development ready for the market. Then you can retire in good spirits.
“The lady would be pleased to be proven that the inventions made in her laboratory really work. And I myself would be satisfied, because it would be proven that one Finnish bioscientist corresponds to ten Yankees. ”
Like in the Winter War, but in a different direction.
"There's a tenfold amount of people and funding in bio-companies, but we're still on schedule."
There is no danger that Jalkanen will get bored even in retirement. He plans to write memoirs, count whitefish nets and watch the stars.
As a little boy, one Christmas he and his brothers received a mirror telescope from Santa. For the boys looked at the sky on many bright frosty evenings.
“I saw the galaxy of Andromeda, the moons of Jupiter and the rings of Saturn. In my work, the interest has focused on the biological nature of man. When the time is right, maybe I'll start exploring other universes. ”
Ps. On the day this story appeared, Jalkanen told another piece of news. The scientific publication Intensive Care Medicine has published a research report on the negative mechanism of action of cortisone in lung injury patients - in other words, a phenomenon that emerged as a byproduct of the traumatic phase three of Trauma and has now been confirmed by laboratory studies. Now the WHO also recommends that cortisone not be used to treat COVID19 patients.

--- END

The best moment of Jalkanen’s career so far is related to Faro’s other drug under development, the anticancer drug Clevegen.
Its principle of operation is connected with the basic biological miracles of life. When a new person begins to develop in the mother’s womb, it contains half of the father’s genes, from the point of view of the mother’s body, foreign material. In order for the body not to reject the fetus, something must be done for the mother’s immune system. From the bone marrow, so-called myeloid cells migrate into the placenta, building a protective wall between the mother’s immune system and the fetus.
“Litter cancer has introduced the same remedy. With it, it goes into hiding from the defense system, ”says Jalkanen.
The drug developed by Faro seeks to act on those cells that lower immunity and thus strengthen the immune system of a cancer patient. At this stage, the medicine has only been tested in patients who have already gone through all other possible treatments and nothing has worked.
“It was a warm feeling when I first saw pictures of a cancer patient’s lungs, where after three treatments in ten weeks, the tumor had shrunk by 60 percent,” Jalkanen says.
“If this works, cancer can only be a chronic disease. Sudden deaths can be avoided. ”
When successful, drugs not only save lives but also generate money. Jalkas already has a foundation ready for that. So far, its balance sheet is modest and the scholarships awarded amount to a few thousand euros. But if Faro's medicines will one day generate millions, the proceeds will be channeled through the foundation to fund high-quality medical research in Finland

A gloomy day in Salisbury
The worst place in Jalkanen’s career was one Thursday in May two years ago. He had traveled to London near Salisbury - a region where Russian ex-spy Sergei Skripal had been poisoned in the same spring - to hear the results of the lung drug Traumakinen’s so-called phase three.
Drug development proceeds in tightly controlled phases called phases. There are three stages before a marketing authorization is granted and a fourth after it. The traumatic phase two was a great success. It had been tested in 2010–11 with promising results for, among others, swine flu patients.
Jalkanen considered the success of the third phase so certain that the company had already begun preparations for marketing the drug. As this is a hospital medicine used in intensive care and Faron has extensive contacts with European and American intensive care hospitals, the idea was to market the product itself. Another option would have been to sell the license to a larger pharmaceutical company.
A shock awaited in Salisbury. Mortality was equal in the drug-treated experimental group and the control group. The lung medicine had not worked.
"It was the darkest day of my life."
The next day, Jalkanen had to take the crushing information to the Faroese government. The following Monday, the news had to be made public. On the stock exchange, 90 percent of Faro's market capitalization was lost in two weeks.
Jalkanen still remembers the thought that started banging in his head as soon as he got the results in front of him. More information is a must. An explanation must be found.
The data were further analyzed and within a few months an explanation was found. Traumakine had not been effective in patients who had also received cortisone treatment.
“I don’t want to blame clinicians, but cortisone has become a habit to prescribe even in cases where there is no proven benefit from its use. The traumatic phase three was an expensive study, but if it results in a reduction in unnecessary cortisone use, it was a cheap study for humanity. ”
The third phase is now performed again so that patients receiving cortisone are in their own group. Jalkanen is convinced that this time the research will be successful and the product will soon be on the market. This is clearly also believed by the WHO, as Faro was invited to participate in the covid-19 study.
Although the unfortunate test collapsed the value of Faro's share, Jalkanen has not lost his night's sleep.
“As CEO, I talk to investors so I don’t promise too much. There must be a time buffer in everything to maintain trust

“It can be turned into a kick, but in a friendly spirit, those negotiations took place. Coldly, we just disagreed. ”
Since then, Biotie Therapies has been sold in the United States. Otherwise, it doesn’t bother Jalk, but it’s annoying that an invention by his own research team remained on the shelf at Biotie when the company’s priorities changed.
“We were very close to success in developing bioheparin. Heparin is an anticoagulant without which modern medicine cannot do without it. At present, it comes from the slaughter waste of Chinese pigs. Our product could have replaced heparin of animal origin. ”
Another thing that annoys the Leg is money. Why is it so difficult to get it into drug development in Finland today?
Faron Pharmaceuticals, founded in 2007, was first listed on the London Stock Exchange because Jalkanen did not believe that they could raise the funds needed for drug development from Finland. In the UK, investing in drug development has a longer tradition and understanding of the time span, risks and return potential of the industry. Faro did not list on the Helsinki Stock Exchange until six months ago.
Jalkanen believes that investing more in drug development could bring significant wealth to Finland. As an example, he cites the hormone coil developed by Leiras, which has been making corporate taxes for millions of years for Finland and Turku for three decades. The Mirena coil is currently manufactured by the German pharmaceutical giant Bayer, but the factory is still in Turku. Mirena is sold worldwide for more than a billion euros every year.
If Faro's drug candidates soon enter the market successfully, they may open the way for other drug developers as well, Jalkanen ponders.
"As in the gaming industry, the success of a few has made investors believe in others

Silicon Valley decided the direction
Without years in California, Markku Jalkan would hardly have become the CEO of a drug development company.
After Mr. Jalkanen's army, a couple of researchers **** went to Stanford University as postdoctoral researchers. Markku Jalkanen wanted to learn more about cells: how do they know what they need to differentiate? When everything leaves the egg, how in the division stage does the brain cell become a brain cell, the skin cell a skin cell? Jalkanen wanted to know who would tell them and if they could tell him.
"It felt like we were close to finding out the secrets of life."
Jalkanen’s Doctoral Research had been related to connective tissues, and he concluded that connective tissue plays a role in the communication that results in cells understanding their environment and differentiating. At Stanford, he joined a research group that wanted to take forward just such molecular biological analytics.
“I had a table set there there. I came out of there with a whole new type of molecular group. The interesting detail is that I still receive, 35 years later, royalties from Stanford for the antibody I characterized. ”
The antibody found by Jalkanen is currently used to analyze types of bone marrow cancer called myeloma. Companies pay a license fee to the university for its use, and the university pays some to the inventors.
"A small amount, but it's a funny concrete memory of that time."
However, the most significant thing about the time in California was that Jalkanen saw with his own eyes how the findings of academic research are processed into practical applications.
“I realized that that information is too valuable to leave in the desktop tray. I began to be fascinated by the opportunity to turn it into something that benefits people. ”
Money and projects meet
The final impetus for a career as a researcher in the business world took place in Turku in the mid-1990s. Jalkanen's family had returned to Turku, and Markku Jalkanen had ended up as the director of the joint biotechnology center of the University of Turku and Åbo Akademi University. One day he received a guest from Helsinki, Kalevi Kurkijärvi, director of Sitra's biofund. "He said: I have heard that you have a lot of projects but no money, I have a vice-versa. What could be done? ”
This is how Biotie Therapies, Finland's first listed biological drug developer, began.

“At first, the lady stabbed me. For him, it was not wise for me to give up a professorship because of a risky venture. But I was in my forties and I think I’ve seen the academic world enough. I had received a little Nobel Prize in medicine and a full professorship and wanted to see what life could be like on the side of drug development. ”
Jalkanen's career at Biotie ended in 2002 with differences of opinion between the CEO and the owners. Biotie had merged with a couple of other companies, and the new private equity investors disagreed with Jalkanen about the company's operat

Fateful evening in Ilokivi
The first lucky coincidence in Jalkanen's career was the birth. He hit a family with a chemist mother, a commercial gardener father, five sons and an imaginative spirit. In the 1960s, boys buried newspapers on spruce cloth because Dad wanted to try whether ear fungi would grow better with a cellulose diet. Increased. Sometimes the children did their own experiments in the mother’s laboratory.
"The miracle that I am alive," Jalkanen says and laughs. The lab didn’t explode, and the boys inherited a curiosity and a creative attitude as a family heirloom. "When the tricks are over, there are tricks left."
The next turning point was perhaps the most important. In the spring of 1973, shortly after his student writings, Jalkanen went with his big brother's papers to the Jyväskylä Student Union's restaurant Ilokiveen. He asked one girl to dance and after the dance to his table to chat. The girl did not come to the table, but later that evening walked past and smiled.
“Who goes to the bathroom. So I got her to dance again. ”
The term power couple may not have been known in Central Finland in the 1970s, and Markku and Sirpa Jalkanen, as long German readers, would not have characterized themselves in English anyway. Such a one of them both grew up, a medical powerhouse.
47 years later, Jalkas has three children - a cancer doctor, a vascular surgeon and a medical researcher - 11 grandchildren and intersecting careers.

“It’s no secret that the inventions underlying the drugs developed by Faro are from Mrs. Jalkanen’s laboratory. We could discuss them at the breakfast table, but we try to avoid it, ”says Markku Jalkanen.
When he talks about his wife, he is not saying Sirpa but “lady” or “academic”. Sirpa Jalkanen is a professor of immunology at the University of Turku with the title of Academician of Science. He is an internationally acclaimed cancer researcher whose research team has changed the way medicine perceives the functioning of the human immune system and vascular biology. The group led by Sirpa Jalkanen has found exactly the molecules responsible for the spread of cancer that Clonegen, a drug developed by Faro, is trying to affect.
Initially, Sirpa Jalkanen did not intend to be a researcher but a pediatrician. He was thrown into the career of a researcher by the realities of family life. When Markku Jalkanen turned 26, he could no longer postpone his military service. During the man's army, it became impossible for the mother of three young children to continue working nights as a doctor, so she switched to day work as a researcher

If you can hope, then thank you not this disease. In its final stage, the walls of the pulmonary capillaries fail and fluid seeps through the vessels into the lungs. Man drowns in his own fluids.
The painful chain of events is called ARDS, sudden respiratory distress syndrome. This lung injury is particularly topical this spring because it causes a significant proportion of coronavirus deaths.
The people of Faron Pharmaceuticals, a Turku-based biopharmaceutical company, have a habit of raising glasses of bubbling in honor of the good news, and on May Day 2020, the cups were lifted remotely in a video conference. There were two reasons for the celebration: Traumakine, a lung injury drug under investigation, had just been selected for a World Health Organization study looking at ways to improve the chances of survival for covid-19 patients. It is a biological drug that Faro has been developing for more than a decade to treat just that vicious ARDS. If the study is successful, it is likely to speed up the process of obtaining a drug license.

Another piece of good news was the continued funding of the anticancer drug candidate Clevegen. In April, Faro managed to raise € 14 million through a share issue to expand its research into a number of difficult-to-treat cancers, including bowel, ovarian, liver and pancreatic cancers.
When Traumakine and Clevegen will one day be ready for medication, Faro's CEO Markku Jalkanen has achieved the goal he has been aiming for since the 1980s.

Big risks, big potential
"You don't believe this, but man has a capillary network of a hundred thousand miles!"

Friday afternoon is already long, but the video call screen shows an enthusiastic CEO who doesn’t seem to be in a hurry to spend the weekend. Markku Jalkanen talks about the length of the human capillaries, because the cell on the surface of the vessels is related to the action of drugs developed by Faro. One hundred thousand kilometers of vein is undeniably a lot, two and a half times around the globe.

Jalkanen talks about medical issues so immersively that for a while even a layman feels that he understands something. It is an essential skill for the CEO of a drug development company, because without investor insurance, there is no whole company. The development of a new drug will take several years and hundreds of millions of euros. Donors must wait patiently and believe that the end result is worth the effort. The risks are big, but so is the potential value.

“It is said that those who invest in drug development are asked about toughness and thick leather. They are only required from the leader of drug development, ”says Jalkanen.
He is a pioneer in the development of biopharmaceuticals in Finland, and the task of a pioneer is not easy. The foot has been helped by a strong belief in science and one’s own abilities.
“I have always had tremendous self-confidence. If someone knows how to do something, I think yes I better do it. As a young man, I

Well done zumzum, thanks for that!

This is all I can get...

Zumzum do you subscribe to this paper and if so can you post a google translation of it here please ?

Biopharmaceutical developer Markku Jalkanen already has a foundation for potential millions: "If we succeed, cancer can only be a chronic disease"

Biomedical pioneer Markku Jalkanen is close to great success. "I was confident at a young age that I would come up with big biological issues in my career.

If you can hope, then thank you not this disease. In its final stages, the walls of the pulmonary vasculature fail and fluid seeps through the vessels into the lungs. M
an drowns in his own fluids.

Thanks for the translation marymoo.

Makes sense really.

But I would like a peek at any results

Drac, i think so

That's a google translation... any Finnish here can give a more accurate translations?

I think he is saying they are waiting on full results before they release any news?

https://twitter.com/KariTikkinen/status/1263149588464222211?s=19

"Kesäkuussa tulee lisätietoja kysymyksiisi, @AunioTouko. Tuhansia on rekrytoitu, mutta nyt mennään aiemmilla spekseillä toistaiseksi ja haetaan luotettavaa tietoa tämän hetken asetelmalla eikä hötkyillä"

"In June, there will be more information for your questions, @AunioTouko. Thousands have been recruited, but now we are going with previous specs so far and looking for reliable information with the current setup and not the gimmicks"

For the believers

11:24:52 20-May-2020 356.00 GBX 1 3.56

I reckon a tr1 might come soon based on the AGM money being piled back into shares by the BOD

Pure guess!

https://www.linkedin.com/posts/riinapalmroth_clinicaltrials-constantlearning-itsallaboutpeople-activity-6666989404151697408-Aost

https://twitter.com/KariTikkinen/status/1261955252884049922?s=09